Free Trial

Theseus Pharmaceuticals (THRX) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
Theseus Pharmaceuticals Announces Closing of Tender Offer
Short Interest in Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) Drops By 37.4%
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 585,500 shares, a drop of 37.4% from the December 15th total of 936,000 shares. Based on an average daily volume of 690,600 shares, the short-interest ratio is presently 0.8 days. Currently, 3.8% of the company's shares are sold short.
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) Short Interest Update
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 936,000 shares, a drop of 42.2% from the November 30th total of 1,620,000 shares. Based on an average daily volume of 620,000 shares, the short-interest ratio is presently 1.5 days. Currently, 6.1% of the company's shares are short sold.
Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash
Theseus Pharmaceuticals Inc THRX
Theseus Pharmaceuticals, Inc. Expected to Earn Q3 2023 Earnings of ($0.37) Per Share (NASDAQ:THRX)
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Free Report) - Stock analysts at Wedbush boosted their Q3 2023 earnings estimates for shares of Theseus Pharmaceuticals in a report issued on Thursday, August 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) Expected to Post Q1 2024 Earnings of ($0.33) Per Share
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX - Free Report) - Wedbush issued their Q1 2024 earnings estimates for Theseus Pharmaceuticals in a research report issued on Thursday, August 10th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.33) per share for th
Theseus Pharmaceuticals (NASDAQ:THRX) Price Target Lowered to $7.00 at Cantor Fitzgerald
Cantor Fitzgerald dropped their target price on shares of Theseus Pharmaceuticals from $23.00 to $7.00 and set an "overweight" rating for the company in a research report on Friday.
Analyst Expectations for Theseus Pharmaceuticals's Future
Theseus Pharmaceuticals Terminates Development Of THE-630
Get Theseus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for THRX and its competitors with MarketBeat's FREE daily newsletter.

Tech GIANT’s Plans to Revolutionize Crypto… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

THRX Media Mentions By Week

THRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

THRX
News Sentiment

0.00

0.80

Average
Medical
News Sentiment

THRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

THRX Articles
This Week

1

1

THRX Articles
Average Week

Get Theseus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for THRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:THRX) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners